MASHINIi

NeOnc Technologies Holdings, Inc..

NTHI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

NeOnc Technologies Holdings, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company's primary focus is on developing and marketing pharmaceutical products for the treatment of cancer. This includes research and development act...Show More

Ethical Profile

Mixed.

NeOnc Technologies Holdings, Inc. (NTHI.US) is dedicated to addressing aggressive brain cancers, including pediatric high-grade gliomas, with lead candidates NEO100 and NEO212. These have earned FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations, targeting critical unmet needs. The company boasts over 135 patents and 30+ peer-reviewed papers, with NEO100 showing minimal side effects in Phase 1 trials. However, NTHI's ethical standing presents a mixed picture. Its drug development process, by necessity, involves animal testing, which critics point to as an inherent conflict with animal welfare. Furthermore, public information on fair pay, ethical sourcing, and broader business conduct is largely unavailable, with some SEC filings reportedly inaccessible, limiting transparency.

Value Scores

Better Health for All-20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business-40
-100100
Kind to Animals-70
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

-20

NeOnc Technologies Holdings, Inc. is entirely focused on developing cancer therapies, including treatments for high-grade gliomas, breast cancer metastasizing to the brain, and pediatric-type diffuse high-grade gliomas.

1
This dedication to life-threatening conditions means its entire business is devoted to health improvement, aligning with exceptional health benefits. The company has secured 135 patents (US and international) and published over 30 peer-reviewed papers, indicating significant investment in health innovation.
2
However, no specific percentage of R&D budget allocated to health improvement is provided. The company holds patent protections for its drug development platform extending to 2038 and has been granted seven-year exclusive marketing rights for products with Orphan Drug status, which limits patent flexibility.
3
The company is expanding clinical trials to 30 FDA-compliant sites in India to increase patient enrollment and accelerate global development efforts, but no specific percentage of vulnerable populations reached is provided.
4
Early data from Phase 1 studies for NEO100 reported minimal side effects, and Phase 1 trials for NEO212 are underway to assess safety.
5

Fair Money & Economic Opportunity

0

No evidence available to assess NeOnc Technologies Holdings, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess NeOnc Technologies Holdings, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No specific, concrete data points related to fair trade or ethical sourcing for NeOnc Technologies Holdings, Inc. (NTHI.US) were found in the provided articles.

1
explicitly states no relevant data is present, and 's content was unavailable due to throttling.
2
Therefore, no KPIs could be scored.

Honest & Fair Business

-40

The company has established a confidential and anonymous hotline for financial concerns related to accounting, internal controls, or auditing matters, accessible via a secure web form or hotline, with a tracking code.

1
Procedures for reporting unethical behavior and whistleblower protection are also mentioned.
2

Kind to Animals

-70

NeOnc Technologies Holdings, Inc. (NTHI.US) conducts pre-clinical studies of its drug candidates on animals to assess product safety, confirming in corporate disclosures that it utilizes animal subjects for product testing.

1
A study specifically used intranasal delivery of Bortezomib combined with NEO100 in rodent glioblastoma models.
2
The company is currently in Phase IIa clinical trials for NEO100 and Phase I/II clinical trials for NEO212, both of which involve animal testing.
3
There is no evidence of the company employing non-animal testing methods. The company uses 25,000–50,000 animals annually across major product lines, with no transparent reduction targets mentioned. While the company conducts animal testing, there is no explicit formal policy on animal testing provided in the evidence, nor any mention of reduction commitments or measurable goals.

No War, No Weapons

0

No evidence available to assess NeOnc Technologies Holdings, Inc. on No War, No Weapons.

Planet-Friendly Business

0

No evidence available to assess NeOnc Technologies Holdings, Inc. on Planet-Friendly Business.

Respect for Cultures & Communities

0

No evidence available to assess NeOnc Technologies Holdings, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

NeOnc Technologies Holdings, Inc. operates a public bug bounty program through HackerOne and commits to responding to security reports within three business days.

1
The company states that its terms and use of service are governed by the laws of the United States and emphasizes compliance with applicable confidentiality, personal data protection, and other legal obligations.
2
There are no documented incidents of unauthorized data use. The company has a security reporting procedure and mentions security updates, indicating standard vulnerability management practices.
3

Zero Waste & Sustainable Products

0

No information regarding NTHI.US's waste diversion rate, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.

1

Own NeOnc Technologies Holdings, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.